Anika Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $30,615 | $27,817 | $28,219 | $26,168 |
Gross Profit | 19,179 | 15,584 | 14,363 | 14,681 |
EBITDA | 2,200 | -833 | -2,764 | -2,692 |
EBIT | 882 | -2,236 | -4,180 | -4,284 |
Net Income | 292 | -2,329 | -3,970 | -4,873 |
Net Change In Cash | 30,615 | 27,817 | 28,219 | 26,168 |
Free Cash Flow | 3,989 | 4,983 | -1,656 | -2,954 |
Cash | 57,481 | 57,990 | 53,167 | 53,371 |
Basic Shares | 14,669 | 14,361 | 14,331 | 14,297 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $112,819 | $119,907 | $120,792 | $156,236 |
Gross Profit | 63,807 | 75,998 | 82,532 | 93,576 |
EBITDA | -1,834 | 3,020 | 15,061 | -4,913 |
EBIT | -7,563 | -5,101 | 844 | -19,400 |
Net Income | -10,880 | -56,385 | -82,667 | -14,859 |
Net Change In Cash | 112,819 | 119,907 | 120,792 | 156,236 |
Cost of Revenue | -7,929 | |||
Free Cash Flow | 4,362 | -2,331 | -7,215 | -3,077 |
Cash | 57,481 | 55,629 | 68,740 | 86,327 |
Basic Shares | 14,339 | 14,721 | 14,656 | 14,561 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0.31 |
2025-09-30 | $0.04 |
2025-06-30 | -$0.33 |
